Up­dat­ed: Mer­ck com­mits up to $610M to buy out pre­clin­i­cal biotech and its neu­rode­gen­er­a­tive dis­ease work

Mer­ck is snap­ping up a pri­vate biotech fo­cused on ge­net­i­cal­ly de­fined neu­rode­gen­er­a­tive dis­or­ders and rare dis­eases, promis­ing to pay $610 mil­lion if every­thing works out.

Car­away Ther­a­peu­tics, based in Cam­bridge, MA, is de­vel­op­ing a slate of pre­clin­i­cal small mol­e­cule ther­a­peu­tics “that boost cel­lu­lar clear­ance path­ways to re­store bal­ance” — with a fo­cus on purg­ing tox­ic pro­teins from cells, such as tau and al­pha-synu­cle­in.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER